United States: Viking Therapeutics Announces $632.5 Million Public Offering Of Common Stock - Cooley LLP
Wednesday, 13 March 2024
Cooley advised the underwriters of Viking Therapeutics (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders...
|
||||
You Might Like |
||||
